Clinical Trials
134 trialsComparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging
Oslo University Hospital
CISTO
University of Washington
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Memorial Sloan Kettering Cancer Center
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
Roswell Park Cancer Institute
TVNIM-AFU
Association Francaise d'Urologie
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
CISTO2
University of Washington
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
ADAPT-BLADDER
Hoosier Cancer Research Network
Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
Assiut University
BladMetrix
Oslo University Hospital
ENHANCE
Hoosier Cancer Research Network
GAIN-BCG
Alliance for Clinical Trials in Oncology
Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
H. Lee Moffitt Cancer Center and Research Institute
VG-INFUSE Tria
Fudan University
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
MiLUT
University of Zurich
PRO-GAG
BLAD-HYA Group
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
Ohio State University Comprehensive Cancer Center
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
University of California, Davis
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital
CRUCIAL-R
S. Andrea Hospital
Hydeal Cyst
Istituto Oncologico Veneto IRCCS
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
Mayo Clinic
En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer
Aarhus University Hospital
SPICE
University of Aarhus
PERTINENCE
Institut Cancerologie de l'Ouest
CUT-less
University of Roma La Sapienza
BicaBCa
CHU de Quebec-Universite Laval
TRAIN
The Christie NHS Foundation Trust
PERSEVERANCE
Institut Cancerologie de l'Ouest
NMIBC
Xijing Hospital
ALU
Hopital Foch
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Johns Hopkins University
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HERO
Fudan University
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
COBRA-NMIBC
Aarhus University Hospital
GEM-IR-NMIBC
Shanghai University of Traditional Chinese Medicine
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Lahey Clinic
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
Ractigen Therapeutics.
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
University of Texas Southwestern Medical Center
RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients
Peking University First Hospital
BCG-TIME
Queen's University
Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing Therapy
Peking University First Hospital
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing
The First Affiliated Hospital with Nanjing Medical University
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
Memorial Sloan Kettering Cancer Center
COBRA
Medical University of Vienna